“The Birth of BioFabUSA: Manufacturing the Future of Biofabrication”
Richard McFarland, PhD, MD is the Chief Regulatory Officer of ARMI/BioFabUSA, , an institute within the Manufacturing USA network. The institute’s goals include creating an industrial commons with the aims to coalesce the field and provide a route for nascent product concepts in TE/RM to reach the marketplace. Prior to ARMI, Dr. McFarland was Associate Director for Policy of the Office of Tissues and Advanced Therapies at the Food and Drug Administration’s Center for Biologics Evaluation and Research (FDA/CBER). He served at the FDA in various positions, and was heavily involved in policy development for tissue engineering, regenerative medicine, and alternatives to animal use in regulatory decision making. In addition to development of risk-based regulatory oversight paradigms within FDA, his interests included broader efforts to create an interlocking network of interagency efforts to foster growth of basic and translational science to support maturation of the overlapping fields of tissue engineering and regenerative medicine from primarily discovery science toward a stage of commercial development.
Dr. McFarland, Ph.D., M. D. received his B.S., Ph.D., and M.D. from the University of North Carolina at Chapel Hill, and completed his anatomic/clinical pathology residency and immunopathology fellowship training at UT Southwestern in Dallas. Immediately prior to joining the FDA, he was on the faculty of the Pathology Department of the University of Texas Southwestern in Dallas. In addition to FDA policy documents he has co-authored over 25 articles in peer-reviewed articles journals including Nature, the Proceedings of the National Academy of Science (PNAS), and Blood.